View the Inspirational Notes published in this journal

Profiles of our editorial board

Exclusively focused on translational aspects of drug delivery, this journal provides a unique forum for publication of high-quality research.

Drug Delivery and Translational Research publishes research focused on such topics as designing and developing novel drug delivery systems, with a focus on their application to disease conditions; preclinical and clinical data related to drug delivery systems; short-term and long-term biocompatibility of drug delivery systems, host response; biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; image-guided drug therapy; nanomedicine; devices for drug delivery and drug/device combination products.

In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to activities of the Controlled Release Society.

Drug Delivery and Translational Research publishes six issues a year.

  • Accepted by ISI in SCIE, Biosis Previews and Biological Abstracts
  • Explores the effect in different disease conditions of rationally developed, effective delivery systems
  • Focuses on high-quality research on the development of novel drug delivery systems
  • Presents full-length papers, communications, and reviews, editorials and more

Journal information

Editor-in-Chief
  • Maria Jose Alonso
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

2.664 (2019)
Impact factor
3.041 (2019)
Five year impact factor
41 days
Submission to first decision
137 days
Submission to acceptance
196,391 (2020)
Downloads

Latest issue

Volume 11

Issue 2, April 2021

A Perspective of Drug Delivery and Translational Research in Europe. Guest Editors: María J. Blanco‑Prieto and Helena F. Florindo

Latest articles

This journal has 83 open access articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

  • 2020 DDTR Best Paper of the Year

    Congratulations to the authors of Translational studies of intravenous and intracerebroventricular routes of administration for CNS cellular biodistribution for BMN 250, an enzyme replacement therapy for the treatment of Sanfilippo type B for winning the DDTR Best Paper of the Year Award for 2020.

    New Content ItemSummary: Treatment of the neurological manifestations of lysosomal storage diseases remains an unmet medical need. BMN 250 is being developed as an enzyme replacement therapy administered directly into the brain ventricles via the intracerebroventricular (ICV) route for treating Sanfilippo type B.  Patients with this rare neurological disease have deficient lysosomal alpha-N-acetylglucosaminidase (NAGLU) enzyme activity. Unlike the ICV route that readily provides biodistribution of therapy to target cells, we show in wild-type and disease animal models that intravenously-administered enzyme does not reach the target neuronal cells. The limited pharmacological response following intravenous administration is likely attributed to the clearance of substrate in endothelial cells that restrict biodistribution to target cells in the brain. Representative staining from superficial medulla oblongata from cynomolgus monkey received BMN 250 via the IV route shows that all NAGLU staining is co-localized with CD31-positive endothelial cells, indicating that IV administered NAGLU does not reach the target neurons. In contrast, NAGLU co-localizes with the neurons following ICV administration.

View all updates

Societies, partners and affiliations

Subscribe

eJournal
$79.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
2190-3948
Print ISSN
2190-393X
Abstracted and indexed in
  1. CNKI
  2. Chemical Abstracts Service (CAS)
  3. Dimensions
  4. EBSCO Discovery Service
  5. EMBASE
  6. Google Scholar
  7. Institute of Scientific and Technical Information of China
  8. Japanese Science and Technology Agency (JST)
  9. Journal Citation Reports/Science Edition
  10. Medline
  11. Meta
  12. Naver
  13. OCLC WorldCat Discovery Service
  14. ProQuest-ExLibris Primo
  15. ProQuest-ExLibris Summon
  16. Reaxys
  17. SCImago
  18. SCOPUS
  19. Science Citation Index Expanded (SciSearch)
  20. TD Net Discovery Service
  21. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Controlled Release Society